1014691-61-2 | 2-Thiophenecarboxylic acid, 3-[[[2-methoxy-4-(phenylamino)phenyl]amino]sulfonyl]-, methyl ester

Packsize	Purity	Availability	Price	Discounted Price
1mg	95%	in stock	$32.00	$22.00
5mg	95%	in stock	$73.00	$51.00
10mg	95%	in stock	$99.00	$69.00
25mg	95%	in stock	$140.00	$98.00
100mg	95%	in stock	$412.00	$288.00

Description

• Catalog Number: AA05678
• Chemical Name: 2-Thiophenecarboxylic acid, 3-[[[2-methoxy-4-(phenylamino)phenyl]amino]sulfonyl]-, methyl ester
• CAS Number: 1014691-61-2
• Molecular Formula: C19H18N2O5S2
• Molecular Weight: 418.4866
• MDL Number: MFCD12828770
• SMILES: COC(=O)c1sccc1S(=O)(=O)Nc1ccc(cc1OC)Nc1ccccc1

Computed Properties

• Complexity: 618
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 28
• Hydrogen Bond Acceptor Count: 8
• Hydrogen Bond Donor Count: 2
• Rotatable Bond Count: 8
• XLogP3: 3.8

Literature

• Perfluorooctanoate suppresses spheroid attachment on endometrial epithelial cells through peroxisome proliferator-activated receptor alpha and down-regulation of Wnt signaling.

  Reproductive toxicology (Elmsford, N.Y.) 20131201

• Peroxisome proliferator-activated receptor delta antagonists inhibit hepatitis C virus RNA replication.

  Bioorganic & medicinal chemistry letters 20130901

• Isorhamnetin inhibits proliferation and invasion and induces apoptosis through the modulation of peroxisome proliferator-activated receptor γ activation pathway in gastric cancer.

  The Journal of biological chemistry 20121102

• (Z)-2-(2-bromophenyl)-3-{[4-(1-methyl-piperazine)amino]phenyl}acrylonitrile (DG172): an orally bioavailable PPARβ/δ-selective ligand with inverse agonistic properties.

  Journal of medicinal chemistry 20120322

• Development of improved PPARβ/δ inhibitors.

  ChemMedChem 20120102

• Skin-targeted inhibition of PPAR β/δ by selective antagonists to treat PPAR β/δ-mediated psoriasis-like skin disease in vivo.

  PloS one 20120101

• High-affinity peroxisome proliferator-activated receptor β/δ-specific ligands with pure antagonistic or inverse agonistic properties.

  Molecular pharmacology 20111101

• Administration of PPARβ/δ agonist reduces copper-induced liver damage in mice: possible implications in clinical practice.

  Journal of clinical biochemistry and nutrition 20110701

• Bezafibrate enhances proliferation and differentiation of osteoblastic MC3T3-E1 cells via AMPK and eNOS activation.

  Acta pharmacologica Sinica 20110501

• The decreased expression of peroxisome proliferator-activated receptors delta (PPARdelta) is reversed by digoxin in the heart of diabetic rats.

  Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20100801

• Evidence for the role of peroxisome proliferator-activated receptor-beta/delta in the development of spinal cord injury.

  The Journal of pharmacology and experimental therapeutics 20100501

• Activation of peroxisome proliferator-activated receptor-{delta} by GW501516 prevents fatty acid-induced nuclear factor-{kappa}B activation and insulin resistance in skeletal muscle cells.

  Endocrinology 20100401

• Identification and characterization of 4-chloro-N-(2-{[5-trifluoromethyl)-2-pyridyl]sulfonyl}ethyl)benzamide (GSK3787), a selective and irreversible peroxisome proliferator-activated receptor delta (PPARdelta) antagonist.

  Journal of medicinal chemistry 20100225

• Endothelium-dependent vasodilator effects of peroxisome proliferator-activated receptor beta agonists via the phosphatidyl-inositol-3 kinase-Akt pathway.

  The Journal of pharmacology and experimental therapeutics 20100201

• Identification and characterization of a selective peroxisome proliferator-activated receptor beta/delta (NR1C2) antagonist.

  Molecular endocrinology (Baltimore, Md.)